Cardiologist here. What I find most compelling about SURMOUNT-OSA is the cardiovascular implications. OSA is an independent risk factor for: - Hypertension (2-3x increased risk) - Atrial fibrillation (4x risk) - Heart failure (2.5x risk) - Stroke (2x risk) - Sudden cardiac death (2.5x risk during sleep) The BP reduction of 7-10 mmHg with tirzepatide in OSA patients is comparable to adding an antihypertensive medication. The hs-CRP reduction of 55% suggests reduced systemic inflammation. The improvement in nocturnal hypoxemia directly reduces sympathetic nervous system activation, which is the primary mediator of OSA's cardiovascular toxicity. What I want to see next: 1. MACE outcomes data. SURMOUNT-OSA wasn't powered for cardiovascular events. We need a large trial with hard endpoints. 2. AF burden reduction. If tirzepatide reduces AHI in AF patients with OSA, does it reduce AF recurrence after ablation? 3. Heart failure outcomes. OSA is devastatingly common in HFpEF (>50% prevalence). Could tirzepatide address both the obesity and the OSA in this population? I'm already incorporating GLP-1 therapy into my management of obese patients with OSA and cardiovascular disease. The triple benefit (weight, OSA, CV risk) makes it one of the highest-yield interventions we have.

Sleep technologist perspective: the practical implications of SURMOUNT-OSA are huge for our labs. I've been doing polysomnography for 12 years. In the past 18 months, I've noticed a clear trend: - More patients coming in for repeat sleep studies after weight loss on GLP-1 drugs - Their AHI values are significantly lower on repeat studies - Many are getting their CPAP pressures reduced or transitioning from CPAP to APAP with lower pressure ranges - A few have had their OSA "resolved" (AHI <5 on diagnostic study) Practical tips for patients getting sleep studies while on GLP-1 therapy: 1. Tell your sleep tech about your GLP-1 medication and weight loss. It matters for interpretation. 2. Don't stop the GLP-1 before the study. We want to see your current state, not your pre-treatment state. 3. If your CPAP feels too strong after weight loss, get a pressure adjustment. Over-pressurized CPAP causes central apneas, mask leak, and aerophagia. Don't just suffer with it. 4. Home sleep tests (HST) are increasingly valid for monitoring. If your insurance allows it, a home study may be sufficient for pressure reassessment. Full in-lab PSG isn't always necessary for follow-up. For clinicians ordering repeat studies: consider APAP (auto-titrating CPAP) instead of fixed-pressure CPAP for patients actively losing weight. APAP adjusts pressure nightly, so the patient's therapy stays optimized as their weight (and optimal pressure) continues to decrease.

makes a great point about APAP. I've switched nearly all my GLP-1 patients to APAP for exactly that reason. The pressure range can auto-adjust as weight decreases, rather than requiring repeat titration studies every time they lose another 20 lbs. To close out my thoughts on this thread — here's how I see the treatment algorithm evolving: Mild OSA (AHI 5-15) + obesity: → GLP-1 therapy first-line (may resolve OSA entirely) → Consider positional therapy or oral appliance as adjunct Moderate OSA (AHI 15-30) + obesity: → GLP-1 therapy + APAP → Reassess at 12 months — if AHI <5 on drug, trial off CPAP with monitoring → If CPAP-intolerant: GLP-1 therapy alone may achieve adequate control Severe OSA (AHI >30) + obesity: → CPAP (non-negotiable for safety) + GLP-1 therapy → Reassess at 12 months for potential CPAP pressure reduction → Consider surgical evaluation if residual OSA despite optimal medical therapy Any severity + OSA with significant anatomical component: → CPAP or surgery + GLP-1 as adjunct for weight management The key paradigm shift: OSA management is no longer CPAP-or-bust. It's a multimodal approach where GLP-1 therapy is a foundational pillar alongside PAP therapy, positional management, oral appliances, and surgery.